What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Lymphoma, Surgery, Oncology and Chemotherapy.
In her study, Prospective cohort study and Pulmonary function testing is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine.
The concepts of her Lymphoma study are interwoven with issues in Clinical trial, Incidence and Tositumomab.
Her work focuses on many connections between Surgery and other disciplines, such as Pediatrics, that overlap with her field of interest in Menopause, Pharmacotherapy, Referral and Cohort.
Her Oncology research incorporates elements of Stanford V, Survival rate, Follicular lymphoma, Survival analysis and Aggressive lymphoma.
Her Chemotherapy research incorporates themes from Platelet, Radiation therapy and Granulocyte.
Her most cited work include:
- A predictive model for aggressive non-Hodgkin's lymphoma (3353 citations)
- Revised response criteria for malignant lymphoma (3306 citations)
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (3188 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Internal medicine, Oncology, Lymphoma, Surgery and Chemotherapy.
Her work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Neutropenia.
Her Oncology study also includes
- Clinical trial which connect with B symptoms,
- Disease that connect with fields like Intensive care medicine.
Her work is dedicated to discovering how Lymphoma, Nuclear medicine are connected with Radioimmunotherapy and other disciplines.
Sandra J. Horning has researched Rituximab in several fields, including Clinical endpoint, Follicular lymphoma, Diffuse large B-cell lymphoma and Phases of clinical research.
Her Stanford V study integrates concerns from other disciplines, such as Survival analysis and BEACOPP.
She most often published in these fields:
- Internal medicine (64.21%)
- Oncology (40.35%)
- Lymphoma (39.30%)
What were the highlights of her more recent work (between 2011-2020)?
- Internal medicine (64.21%)
- Oncology (40.35%)
- Rituximab (21.75%)
In recent papers she was focusing on the following fields of study:
Internal medicine, Oncology, Rituximab, Vincristine and Lymphoma are her primary areas of study.
Her Internal medicine research includes elements of Gastroenterology and Surgery.
Her Oncology study incorporates themes from CHOP, Chemotherapy, Randomized controlled trial, Immunology and Retrospective cohort study.
Sandra J. Horning combines subjects such as Phases of clinical research, Regimen, Clinical endpoint, Follicular lymphoma and Dosing with her study of Rituximab.
Her Vincristine study combines topics in areas such as Survival rate, Mantle cell lymphoma, Nuclear medicine and Prednisone.
Her research in Lymphoma intersects with topics in Methylation, Monoclonal, Virology, Confidence interval and Lytic cycle.
Between 2011 and 2020, her most popular works were:
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma (267 citations)
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) (188 citations)
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience (164 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Her scientific interests lie mostly in Internal medicine, Oncology, Dacarbazine, Rituximab and Vincristine.
Sandra J. Horning focuses mostly in the field of Internal medicine, narrowing it down to matters related to Surgery and, in some cases, Hazard ratio.
Her work carried out in the field of Oncology brings together such families of science as Young adult, Clinical endpoint, Retrospective cohort study and Survival rate.
Her Rituximab research integrates issues from Follicular lymphoma and Phases of clinical research.
Her Vincristine study which covers Prednisone that intersects with Procarbazine.
The various areas that Sandra J. Horning examines in her Bleomycin study include Gastroenterology and Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
